Navigation Links
Researchers use blood testing to predict level of enzymes that facilitate disease progression
Date:11/1/2012

Predicting how atherosclerosis, osteoporosis or cancer will progress or respond to drugs in individual patients is difficult. In a new study, researchers took another step toward that goal by developing a technique able to predict from a blood sample the amount of cathepsinsprotein-degrading enzymes known to accelerate these diseasesa specific person would produce.

This patient-specific information may be helpful in developing personalized approaches to treat these tissue-destructive diseases.

"We measured significant variability in the amount of cathepsins produced by blood samples we collected from healthy individuals, which may indicate that a one-size-fits-all approach of administering cathepsin inhibitors may not be the best strategy for all patients with these conditions," said Manu Platt, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.

The study was published online on Oct. 19, 2012 in the journal Integrative Biology. This work was supported by the National Institutes of Health, Georgia Cancer Coalition, Atlanta Clinical and Translational Science Institute, and the Emory/Georgia Tech Regenerative Engineering and Medicine Center.

Platt and graduate student Keon-Young Park collected blood samples from 14 healthy individuals, removed white blood cells called monocytes from the samples and stimulated those cells with certain molecules so that they would become macrophages or osteoclasts in the laboratory. By doing this, the researchers recreated what happens in the bodymonocytes receive these cues from damaged tissue, leave the blood, and become macrophages or osteoclasts, which are known to contribute to tissue changes that occur in atherosclerosis, cancer and osteoporosis.

Then the researchers developed a model that used patient-varying kinase signals collected from the macrophages or osteoclasts to predict patient-specific activity of four cathepsins: K, L, S and V.

"Kinases are enzymes that integrate stimuli from different soluble, cellular and physical cues to generate specific cellular responses," explained Platt, who is also a Georgia Cancer Coalition Distinguished Cancer Scholar. "By using a systems biology approach to link cell differentiation cues and responses through integration of signals at the kinase level, we were able to mathematically predict relative amounts of cathepsin activity and distinguish which blood donors exhibited greater cathepsin activity compared to others."

Predictability for all cathepsins ranged from 90 to 95 percent for both macrophages and osteoclasts, despite a range in the level of each cathepsin among the blood samples tested.

"We were pleased with the results because our model achieved very high predictability from a simple blood draw and overcame the challenge of incorporating the complex, unknown cues from individual patients' unique genetic and biochemical backgrounds," said Platt.

According to Platt, the next step will be to assess the model's ability to predict cathepsin activity using blood samples from individuals with the diseases of interest: atherosclerosis, osteoporosis or cancer.

"Our ultimate goal is to create an assay that will inform a clinician whether an individual's case of cancer or other tissue-destructive disease will be very aggressive from the moment that individual is diagnosed, which will enable the clinician to develop and begin the best personalized treatment plan immediately," added Platt.


'/>"/>

Contact: John Toon
jtoon@gatech.edu
404-894-6986
Georgia Institute of Technology Research News
Source:Eurekalert  

Related biology news :

1. Researchers identify genetic basis of cardiac, craniofacial birth defects
2. Duke researchers engineer cartilage from pluripotent stem cells
3. NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer
4. Researchers decipher the mecanism of membrane fission
5. SDSU researchers to study Chinas national treasure
6. Exercise boosts satisfaction with life, researchers find
7. UC Davis researchers develop new drug delivery system for bladder cancer using nanoparticles
8. Far from random, evolution follows a predictable genetic pattern, Princeton researchers find
9. USF researchers identify gene mutation linked to old age hearing loss
10. USDA scientists collaborate with global researchers to advance the mapping of the barley genome
11. Danish researchers release ground-breaking knowledge about calcium pumps in cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers use blood testing to predict level of enzymes that facilitate disease progression
(Date:11/24/2016)... IRVINE, Calif. , Nov. 23, 2016 ... help endurance athletes and their trainers non-invasively measure ... Variability Index, Pulse Rate, and Respiration Rate in approximately ... Ember enables users easy and immediate access to key ... as part of a training regimen. ...
(Date:11/21/2016)... Lithuania , Nov. 21, 2016   ... and object recognition technologies, today announced that the ... smart cards was submitted for the NIST ... successfully passed all the mandatory steps of the ... evaluation is a continuing test of fingerprint templates ...
(Date:11/17/2016)... 2016  AIC announces that it has just released a new white paper authored ... scale-out plus high speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of AxioMed’s ... disc production, company President, Jake Lubinski will be traveling to Switzerland from December ... in Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic disc. ...
(Date:12/2/2016)... Amgen (NASDAQ: AMGN ) and Allergan ... of a Marketing Authorization Application (MAA) to the European Medicines ... ® (bevacizumab). The companies believe this submission is the ... "The submission of ABP 215 to the EMA is ... portfolio," said Sean E. Harper , M.D., executive vice ...
(Date:12/2/2016)... San Diego, CA (PRWEB) , ... December 01, 2016 , ... ... safety data from its Phase I/II clinical trials for AC0010 at the World Conference ... look forward to providing an update on the phase I/II clinical trials for AC0010 ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
Breaking Biology Technology: